Եվրոպական Միություն - Նորվեգերեն - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - antineoplastiske midler - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.  yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 og 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.

Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

institut produits synthèse (ipsen) ab - botulinumtoksin type a - haemagglutininkompleks - pulver til injeksjonsvæske, oppløsning - 125 e

Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

abbvie as - deoksykolsyre - injeksjonsvæske, oppløsning - 10 mg/ ml

Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

ge healthcare b.v. - natriummolybdat mo-99 omdannes til natriumperteknetat tc-99m - radionuklidegenerator

Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

curium netherlands b.v. - indium (111in) pentetat - injeksjonsvæske, oppløsning - 37 mbq/ ml

Եվրոպական Միություն - Նորվեգերեն - EMA (European Medicines Agency)

biomarin international limited - pegvaliase - phenylketonurias - andre fordøyelseskanaler og metabolisme produkter - palynziq er indisert for behandling av pasienter med fenylketonuri (pku) i alderen 16 år og eldre som har blod fenylalanin-kontroll (blod fenylalanin nivåer høyere enn 600 micromol/l) til tross for at før ledelsen med tilgjengelig behandlingstilbud.

Եվրոպական Միություն - Նորվեգերեն - EMA (European Medicines Agency)

biotest pharma gmbh - human hepatitis b immunoglobulin - immunization, passive; hepatitis b; liver transplantation - immune sera og immunglobuliner, - forebygging av hepatitt b-virus (hbv) re-infeksjon hos hbsag og hbv-dna-negative voksne pasienter minst en uke etter levertransplantasjon for hepatitt b-indusert leversvikt. hbv-dna-negativ status bør bekreftes i løpet av de siste 3 månedene før olt. pasienter bør være hbsag-negative før behandlingsstart. samtidig bruk av tilstrekkelig virostatic agenter bør betraktes som standard av hepatitt b re-infeksjon prophylaxis.

Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

hexal a/s - klozapin - tablett - 25 mg

Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

hexal a/s - klozapin - tablett - 100 mg

Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

actavis group ptc ehf - klozapin - tablett - 100 mg